978 related articles for article (PubMed ID: 9808682)
1. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
2. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
3. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
[TBL] [Abstract][Full Text] [Related]
4. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
5. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
[TBL] [Abstract][Full Text] [Related]
7. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Wegner M; Hirth-Dietrich C; Stasch JP
Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
[TBL] [Abstract][Full Text] [Related]
8. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
French JF; Flynn GA; Giroux EL; Mehdi S; Anderson B; Beach DC; Koehl JR; Dage RC
J Pharmacol Exp Ther; 1994 Jan; 268(1):180-6. PubMed ID: 8301555
[TBL] [Abstract][Full Text] [Related]
11. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
Seccia TM; Belloni AS; Guidolin D; Sticchi D; Nussdorfer GG; Pessina AC; Rossi GP
J Hypertens; 2006 Jul; 24(7):1419-27. PubMed ID: 16794493
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Gonzalez W; Beslot F; Laboulandine I; Fournié-Zaluski MC; Roques BP; Michel JB
J Pharmacol Exp Ther; 1996 Aug; 278(2):573-81. PubMed ID: 8768706
[TBL] [Abstract][Full Text] [Related]
13. Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction.
Duncan AM; Burrell LM; Kladis A; Campbell DJ
J Cardiovasc Pharmacol; 1996 Dec; 28(6):746-54. PubMed ID: 8961071
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Wallis EJ; Ramsay LE; Hettiarachchi J
Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
[TBL] [Abstract][Full Text] [Related]
15. Vasopeptidase inhibition: a double-edged sword?
Campbell DJ
Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
[TBL] [Abstract][Full Text] [Related]
17. Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery.
Miyamoto A; Murata S; Nishio A
Naunyn Schmiedebergs Arch Pharmacol; 2002 May; 365(5):365-70. PubMed ID: 12012022
[TBL] [Abstract][Full Text] [Related]
18. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
Roques BP
Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
[TBL] [Abstract][Full Text] [Related]
19. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.
Campbell DJ; Kladis A; Duncan AM
Hypertension; 1994 Apr; 23(4):439-49. PubMed ID: 8144213
[TBL] [Abstract][Full Text] [Related]
20. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
Campbell DJ; Zhang Y; Kelly DJ; Gilbert RE; McCarthy DJ; Shi W; Smyth GK
Clin Exp Pharmacol Physiol; 2011 Sep; 38(9):623-31. PubMed ID: 21736602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]